news
CHMP meeting highlights – April 2025
The Committee for Medicinal Products for Human Use (CHMP) recommended approval of a variety of new medicines, including several treatments for hereditary and rare conditions.
List view / Grid view
Drug Development
news
Could investigational drug become first-in-class bronchiectasis therapy?
The small molecule treatment is currently being reviewed by the US Food and Drug Administration (FDA), under the Prescription Drug User Fee Act (PDUFA).
webinar
Achieving rapid microbial method validation with precise reference standard quantification
25 April 2025 | By Rapid Micro Biosystems and ATCC
This webinar explores validation of rapid microbial methods with ready-to-use reference materials, a new industry standard in microbial QC testing.
news
Automated particle image analysis could optimise powder adhesion measurement
The research provides insight into effective measurement of particle adhesion, potentially enhancing pharmaceutical powder processing.
news
Boehringer agrees new partnership to advance first-in-class precision cancer therapies
The collaboration between Boehringer Ingelheim and Tessellate Bio seeks to address availability of targeted medicines for a cancer type shown to be difficult to treat.
news
Antibody treatment demonstrates potential in lupus kidney disease
The findings suggest that the biologic treatment could improve short-term outcomes for patients with lupus nephritis.
news
FDA approves novel therapy for chronic skin condition
The US approval could improve outcomes for eligible patients with previously limited options for managing the inflammatory skin condition.
news
Eli Lilly releases topline data for new oral GLP-1
Subject to regulatory approval, the small molecule drug could provide a new treatment option for diabetes and obesity, Eli Lilly’s new data suggests.
article
From pipettes to processors: how AI Is reshaping pharma’s future
The rise of AI, digital twins, and advanced computational modelling signals a paradigm shift in pharmaceutical R&D. These advances are poised to challenge long-standing methodologies, demanding a workforce capable of navigating an evolving technological landscape. Alistair Henry, UCB’s Chief Scientific Officer, examines how the sector needs to embrace the shift…
news
European Commission Alzheimer’s drug approval marks advancement for EU patients
Lecanemab is the only approved Aβ monoclonal antibody that highly binds to and clears toxic protofibrils with high selectivity.
news
Innovative approach could improve cancer immunotherapy
A clinical trial is currently investigating the potential of CD40L-enhanced tumour-infiltrating lymphocyte (TIL) cancer therapy in non-small cell lung cancer.
news
NICE recommends new combination breast cancer drug
The agency’s recommendation could provide eligible breast cancer patients with a treatment that analysis suggest is to likely to work as well as two medicines already recommended by NICE.
webinar
Reflections and future opportunities in pharmaceutical microbiology
11 April 2025 | By European Pharmaceutical Review
During this virtual panel, industry experts will explore the major challenges, promising innovations and key trends impacting pharmaceutical microbiology.
webinar
What does the future hold for drug formulation in 2025?
11 April 2025 | By European Pharmaceutical Review
During this virtual panel, industry experts will explore the latest innovations and major challenges of drug formulation in the pharmaceutical industry.
news
New analysis sets stage for improved UK clinical trials
Observations from the report will help the MHRA to strengthen clinical research and lay the foundation for accelerated innovation and medicine delivery to patients in the UK.
